Bachem Holding AG

BATS-CHIXE:BANBZ Stock Report

Market Cap: CHF 5.1b

Bachem Holding Valuation

Is BANBZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BANBZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BANBZ (CHF68.55) is trading above our estimate of fair value (CHF24.63)

Significantly Below Fair Value: BANBZ is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BANBZ?

Key metric: As BANBZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BANBZ. This is calculated by dividing BANBZ's market cap by their current earnings.
What is BANBZ's PE Ratio?
PE Ratio45.2x
EarningsCHF 113.57m
Market CapCHF 5.14b

Price to Earnings Ratio vs Peers

How does BANBZ's PE Ratio compare to its peers?

The above table shows the PE ratio for BANBZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.7x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
9.9x-15.2%UK£172.8m
HIK Hikma Pharmaceuticals
17.8x11.2%UK£4.0b
GNS Genus
140.2x37.0%UK£1.1b
BANBZ Bachem Holding
45.2x17.9%CHF 5.1b

Price-To-Earnings vs Peers: BANBZ is good value based on its Price-To-Earnings Ratio (45.2x) compared to the peer average (56x).


Price to Earnings Ratio vs Industry

How does BANBZ's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BANBZ is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the European Life Sciences industry average (37.1x).


Price to Earnings Ratio vs Fair Ratio

What is BANBZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BANBZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.2x
Fair PE Ratio26.9x

Price-To-Earnings vs Fair Ratio: BANBZ is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the estimated Fair Price-To-Earnings Ratio (26.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BANBZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 68.55
CHF 85.00
+24.0%
12.2%CHF 100.00CHF 71.00n/a7
Nov ’25CHF 70.05
CHF 84.83
+21.1%
13.2%CHF 100.00CHF 71.00n/a6
Oct ’25CHF 70.00
CHF 82.83
+18.3%
16.0%CHF 100.00CHF 65.00n/a6
Sep ’25CHF 81.55
CHF 82.83
+1.6%
16.0%CHF 100.00CHF 65.00n/a6
Aug ’25CHF 79.28
CHF 77.14
-2.7%
22.9%CHF 100.00CHF 52.00n/a7
Jul ’25CHF 83.48
CHF 75.67
-9.4%
22.1%CHF 100.00CHF 52.00n/a6
Jun ’25CHF 80.05
CHF 70.80
-11.6%
19.6%CHF 85.00CHF 52.00n/a5
May ’25CHF 80.50
CHF 70.80
-12.0%
19.6%CHF 85.00CHF 52.00n/a5
Apr ’25CHF 86.10
CHF 70.80
-17.8%
19.6%CHF 85.00CHF 52.00n/a5
Mar ’25CHF 70.15
CHF 71.17
+1.4%
17.6%CHF 85.00CHF 52.00n/a6
Feb ’25CHF 58.03
CHF 71.17
+22.6%
17.6%CHF 85.00CHF 52.00n/a6
Jan ’25CHF 65.00
CHF 73.17
+12.6%
13.7%CHF 85.00CHF 56.00n/a6
Dec ’24CHF 64.95
CHF 75.33
+16.0%
9.3%CHF 85.00CHF 64.00n/a6
Nov ’24CHF 66.05
CHF 75.33
+14.1%
9.3%CHF 85.00CHF 64.00CHF 70.056
Oct ’24CHF 67.65
CHF 77.00
+13.8%
12.7%CHF 95.00CHF 64.00CHF 70.006
Sep ’24CHF 82.20
CHF 80.00
-2.7%
14.1%CHF 97.00CHF 65.00CHF 81.557
Aug ’24CHF 80.10
CHF 82.83
+3.4%
13.6%CHF 97.00CHF 65.00CHF 79.286
Jul ’24CHF 77.75
CHF 87.60
+12.7%
9.3%CHF 97.00CHF 74.00CHF 83.485
Jun ’24CHF 93.55
CHF 91.75
-1.9%
4.8%CHF 97.00CHF 86.00CHF 80.054
May ’24CHF 96.90
CHF 88.20
-9.0%
11.2%CHF 100.00CHF 71.00CHF 80.505
Apr ’24CHF 91.95
CHF 88.20
-4.1%
11.2%CHF 100.00CHF 71.00CHF 86.105
Mar ’24CHF 94.00
CHF 88.20
-6.2%
11.2%CHF 100.00CHF 71.00CHF 70.155
Feb ’24CHF 80.70
CHF 86.80
+7.6%
11.7%CHF 100.00CHF 71.00CHF 58.035
Jan ’24CHF 80.45
CHF 86.80
+7.9%
11.7%CHF 100.00CHF 71.00CHF 65.005
Dec ’23CHF 90.20
CHF 74.40
-17.5%
23.4%CHF 95.00CHF 48.00CHF 64.955
Nov ’23CHF 69.15
CHF 72.83
+5.3%
21.0%CHF 95.00CHF 48.00CHF 66.056

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies